Mostrar el registro sencillo del ítem
Discovery of novel TASK-3 channel blockers using a pharmacophore-based virtual screening
dc.contributor.author | Ramírez D. | |
dc.contributor.author | Concha G. | |
dc.contributor.author | Arévalo B. | |
dc.contributor.author | Prent-Peñaloza L. | |
dc.contributor.author | Zúñiga L. | |
dc.contributor.author | Kiper A.K. | |
dc.contributor.author | Rinné S. | |
dc.contributor.author | Reyes-Parada M. | |
dc.contributor.author | Decher N. | |
dc.contributor.author | González W. | |
dc.contributor.author | Caballero J. | |
dc.date.accessioned | 2020-09-02T22:26:32Z | |
dc.date.available | 2020-09-02T22:26:32Z | |
dc.date.issued | 2019 | |
dc.identifier | 10.3390/ijms20164014 | |
dc.identifier.citation | 20, 16, - | |
dc.identifier.issn | 16616596 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12728/5950 | |
dc.description | TASK-3 is a two-pore domain potassium (K2P) channel highly expressed in the hippocampus, cerebellum, and cortex. TASK-3 has been identified as an oncogenic potassium channel and it is overexpressed in different cancer types. For this reason, the development of new TASK-3 blockers could influence the pharmacological treatment of cancer and several neurological conditions. In the present work, we searched for novel TASK-3 blockers by using a virtual screening protocol that includes pharmacophore modeling, molecular docking, and free energy calculations. With this protocol, 19 potential TASK-3 blockers were identified. These molecules were tested in TASK-3 using patch clamp, and one blocker (DR16) was identified with an IC50 = 56.8 ± 3.9 µM. Using DR16 as a scaffold, we designed DR16.1, a novel TASK-3 inhibitor, with an IC50 = 14.2 ± 3.4 µM. Our finding takes on greater relevance considering that not many inhibitory TASK-3 modulators have been reported in the scientific literature until today. These two novel TASK-3 channel inhibitors (DR16 and DR16.1) are the first compounds found using a pharmacophore-based virtual screening and rational drug design protocol. © 2019 by the authors. Licensee MDPI, Basel, Switzerland. | |
dc.language.iso | en | |
dc.publisher | MDPI AG | |
dc.subject | Drug design | |
dc.subject | Lead optimization | |
dc.subject | Pharmacophore-based virtual screening | |
dc.subject | TASK channels blockers | |
dc.subject | TASK-3 channel | |
dc.subject | potassium channel blocking agent | |
dc.subject | KCNK9 protein, human | |
dc.subject | potassium channel blocking agent | |
dc.subject | tandem pore domain potassium channel | |
dc.subject | Article | |
dc.subject | binding site | |
dc.subject | carbon nuclear magnetic resonance | |
dc.subject | controlled study | |
dc.subject | crystal structure | |
dc.subject | Fourier transform infrared spectroscopy | |
dc.subject | high throughput screening | |
dc.subject | human | |
dc.subject | human cell | |
dc.subject | hydrogen bond | |
dc.subject | mass spectrometry | |
dc.subject | molecular docking | |
dc.subject | molecular dynamics | |
dc.subject | patch clamp technique | |
dc.subject | pharmacophore | |
dc.subject | protein conformation | |
dc.subject | protein expression | |
dc.subject | proton nuclear magnetic resonance | |
dc.subject | stereochemistry | |
dc.subject | drug design | |
dc.subject | HEK293 cell line | |
dc.subject | molecular docking | |
dc.subject | Drug Design | |
dc.subject | HEK293 Cells | |
dc.subject | Humans | |
dc.subject | Molecular Docking Simulation | |
dc.subject | Potassium Channel Blockers | |
dc.subject | Potassium Channels, Tandem Pore Domain | |
dc.title | Discovery of novel TASK-3 channel blockers using a pharmacophore-based virtual screening | |
dc.type | Article |